e-learning
resources
Glasgow 2004
Monday 06.09.2004
Lung transplantation: new insights in advanced lung disease and new drug developments - do they impact on selection criteria?
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cystic fibrosis: the problem with
B. cepacia
and more
P. Corris (Newcastle upon Tyne, United Kingdom)
Source:
Annual Congress 2004 - Lung transplantation: new insights in advanced lung disease and new drug developments - do they impact on selection criteria?
Session:
Lung transplantation: new insights in advanced lung disease and new drug developments - do they impact on selection criteria?
Session type:
Assembly Symposium
Number:
2662
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Corris (Newcastle upon Tyne, United Kingdom). Cystic fibrosis: the problem with
B. cepacia
and more. Annual Congress 2004 - Lung transplantation: new insights in advanced lung disease and new drug developments - do they impact on selection criteria?
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Novel therapeutics for cystic fibrosis
Related content which might interest you:
Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients
Source: Eur Respir J 2004; 23: 851-856
Year: 2004
Burkholderia cepacia
complex infection in Czech patients with cystic fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 503s
Year: 2003
Treatment of
Burholderia cepacia
infection in patients with cystic fibrosis
Source: Eur Respir J 2001; 18: Suppl. 33, 539s
Year: 2001
Microevolution of
pseudomonas aeruginosa
in cystic fibrosis lungs
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014
Nebulized heparin in Burkholderia cepacia colonized adult cystic fibrosis patients
Source: Eur Respir J 2001; 17: 36-38
Year: 2001
Temperate bacteriophages of
pseudomonas aeruginosa
as markers of bacterial adaptation in CF and non-CF bronchiectasis
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014
Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre
Source: Eur Respir J 2005; 25: 474-481
Year: 2005
Host specificity of
pseudomonas
aeruginosa
isolates from patients with cystic fibrosis and patients from different clinical backgrounds
Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology
Year: 2014
Cystic fibrosis:
Achromobacter xylosoxidans
colonized patients have more severe respiratory disease
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013
Burkholderia cepacia infection in adult cystic fibrosis patients: Its impact on lung function and survival
Source: Annual Congress 2010 - New aspects of cystic fibrosis
Year: 2010
Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis
Source: Eur Respir J 2007; 30: 286-292
Year: 2007
Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients
Source: Eur Respir J 2008; 31: 822-829
Year: 2008
The spectrum of Nocardia lung disease in cystic fibrosis
Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous
Year: 2015
Achromobacter (A.) xylosoxidans
in cystic fibrosis: prevalence and clinical relevance
Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle
Year: 2005
Factors associated with infection by Pseudomonas aeruginosa in adult cystic fibrosis
Source: Eur Respir J 2005; 26: 651-656
Year: 2005
Eradication of Pseudomonas aeruginosa in cystic fibrosis
Source: Eur Respir J 2006; 27: 438-439
Year: 2006
Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients
Source: Eur Respir J 2006 Oct 01;28(4):740-747
Year: 2006
Pseudomonas aeruginosa from CF airways uses various strategies to outcompete staphylococcus aureus
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016
Pseudomonas aeruginosa transmission is infrequent in New Zealand cystic fibrosis clinics
Source: Eur Respir J 2008; 32: 1583-1590
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept